MedTrace Logo

External Comparison of Ibalizumab in Trials vs. Other Regimens in OPERA

NCT05495204 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 141

Last updated 2023-09-07

No results posted yet for this study

Summary

Among heavily treatment experienced people living with HIV, the virologic effectiveness of ibalizumab + optimized background regimen from two clinical trials will be compared to non-ibalizumab-containing regimens in routine clinical care in the OPERA cohort.

Conditions

Interventions

DRUG

Ibalizumab

Participation in clinical trials vs. routine care in OPERA

Sponsors & Collaborators

  • Theratechnologies

    collaborator INDUSTRY

  • FIECON

    collaborator UNKNOWN

  • Epividian

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-05
Primary Completion
2023-02-20
Completion
2023-02-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05495204 on ClinicalTrials.gov